Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

With three unique projects, all developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.

Download Cyxone’s Significant Accounting Principles as PDF

Investor Relations contact
Tara Heitner, CEO
tara.heitner@cyxone.com

Latest Presentations

Vator Securities Healthcare Innovation Summit

7 October 2021

Redeye Investment Forum 2021, Malmö

30 September 2021

Redeye: Interview with CEO Tara Heitner

2 September 2021

Latest Press Release

  • Cyxone will leverage IND and use FDA pre-review for Covid-19 phase 2 trial

    September 24, 2021 11:19 (CEST)
    Regulatory

    Cyxone AB (publ) announces today that the company is expecting to communicate top-line results from a recently concluded Phase 2 trial of its drug candidate Rabeximod in Covid-19 patients during the fourth quarter. The results were previously slated for the third quarter. The postponement is due to the company’s decision to leverage the U.S. Food and Drug Administration (FDA) initiative to pre-review the statistical analysis plan for the clinical trial, whereby the exact timing of the results will depend on the process and discussion required with the FDA. This is an extraordinary opportunity provided by the authority to expedite the development of safe and efficacious Covid-19 treatments.

    Read more

Financial Calendar

Silent period Q3 2021

Start date: 29 September 2021

End date: 29 October 2021

The interim report for Q3 2021 will be published on 29 October 2021 and the silent period starts 29 September 2021.

Interim Report Q3 2021

Date: 29 October 2021

Silent period Q4, 2021

Start date: 12 January 2022

End date: 11 February 2022

The year-end report 2021 will be published 11 February 2022 and the silent period starts 12 January 2022.